Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Impact of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Considerations for Modeling CYP3A-Mediated Drug-Drug Interactions

This article has not been copyedited and formatted. The final version may differ from this version. Abstract The purpose of this study was to determine the impact of CYP3A5 expression on inhibitory potency (K i or IC 50 values) of CYP3A inhibitors, using recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) and CYP3A5 genotyped human liver microsomes (HLMs). IC 50 ratios between rCYP3A4-and rCYP3...

متن کامل

Potential Drug Interactions in War-Injured Veterans

Drug-drug interaction (DDI) is one of the most important problems in the treatment of patients suffering from different chronic intractable diseases. The war-injured veterans are one of the groups that are prone to chronic refractory diseases. This investigation was conducted on war-injured veterans treated in a multi-disciplinary clinic in Tehran. Using Poisson model, a total of 150 patients w...

متن کامل

Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.

Cryopreserved human hepatocytes suspended in human plasma (HHSHP) represent an integrated metabolic environment for predicting drug-drug interactions (DDIs). In this study, 13 CYP3A reversible and/or time-dependent inhibitors (TDIs) were incubated with HHSHP for 20 min over a range of concentrations after which midazolam 1'-hydroxylation was used to measure CYP3A activity. This single incubatio...

متن کامل

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

Two multicenter, single-arm, single-infusion, open-label studies were conducted to evaluate the effect of ketoconazole (a strong CYP3A inhibitor) or rifampin (a strong CYP3A inducer) daily for 5 days on the pharmacokinetics (PK) and safety of romidepsin (8 mg/m(2) intravenous 4-hour infusion for the ketoconazole study or a 14 mg/m(2) intravenous 4-hour infusion for the rifampin study) in patien...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Antimicrobial Agents and Chemotherapy

سال: 2019

ISSN: 0066-4804,1098-6596

DOI: 10.1128/aac.02016-18